AMF Tjanstepension AB Invests $95.40 Million in Boston Scientific Corporation $BSX

Key Points

• AMF Tjanstepension AB invested approximately $95.40 million in Boston Scientific Corporation by acquiring 888,204 shares, representing 0.06% of the company.
• Boston Scientific's Q2 revenue was reported at $5.06 billion, significantly exceeding the consensus estimate of $4.89 billion, and earnings per share beat expectations as well.
• A number of analysts recently assigned ratings and price targets, with Raymond James increasing their target from $121.00 to $124.00 while Wall Street Zen downgraded the stock from "buy" to "hold."

AMF Tjanstepension AB acquired a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 888,204 shares of the medical equipment provider's stock, valued at approximately $95,402,000. AMF Tjanstepension AB owned 0.06% of Boston Scientific at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. Invesco Ltd. lifted its stake in Boston Scientific by 5.3% in the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock worth $1,677,124,000 after acquiring an additional 834,274 shares during the period. Goldman Sachs Group Inc. lifted its stake in Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock worth $1,426,779,000 after acquiring an additional 1,383,524 shares during the period. Amundi lifted its stake in Boston Scientific by 2.6% in the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock worth $1,212,408,000 after acquiring an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Boston Scientific by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider's stock worth $1,139,938,000 after acquiring an additional 460,580 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 in the last 90 days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

BSX opened at $97.30 on Friday. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market cap of $144.17 billion, a P/E ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. The firm's 50-day moving average price is $102.93 and its 200-day moving average price is $102.05.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday. Raymond James Financial increased their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th. Royal Bank Of Canada reissued an "outperform" rating and set a $125.00 price target on shares of Boston Scientific in a research report on Monday, September 29th. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Needham & Company LLC reissued a "buy" rating and set a $121.00 price target on shares of Boston Scientific in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $120.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.